Priya Bhosale | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Priya Bhosale | Clinical Trials | Best Researcher Award

Professor of radiology at MD Anderson Cancer Center | United States

Dr. Priya Bhosale is a distinguished Professor of Diagnostic Radiology at The University of Texas MD Anderson Cancer Center, specializing in abdominal and gynecologic imaging. With a career marked by academic excellence, clinical leadership, and pioneering research, she has significantly advanced imaging techniques for cancer diagnosis and treatment planning. She has held numerous leadership roles, contributed to international cancer care guidelines, and mentored emerging medical professionals. Renowned for her dedication to innovation and quality improvement, Dr. Bhosale actively participates in professional societies, editorial boards, and multidisciplinary initiatives, striving to enhance patient care, radiology practice standards, and global collaboration in oncologic imaging.

Publication Profile 

Google Scholar

Education 

Dr. Priya Bhosale earned her MD in Medicine from D.Y. Patil Medical College, Kolhapur, India, followed by advanced radiology training at the University of Pennsylvania and a fellowship at MD Anderson Cancer Center. She has pursued multiple leadership, innovation, and management programs at prestigious institutions including MD Anderson, the American College of Radiology, Association of University Radiologists, and Rice University. Her academic credentials also include an MBA in Health Care Management and Corporate Strategy. These diverse educational experiences have equipped her with expertise in clinical excellence, leadership development, strategic planning, quality control, corporate innovation, and emotional intelligence, all applied to medical practice.

Experience 

Dr. Priya Bhosale has served at MD Anderson Cancer Center progressing from Assistant Professor to Professor in Diagnostic Radiology. She holds concurrent appointments at UT Health Science Center in Houston. She has directed numerous programs including the Quantitative Imaging Core, chaired key quality committees, and led gynecologic imaging initiatives. Beyond academic roles, she has contributed to national and international cancer committees, served as course director, and collaborated in multidisciplinary research. Her leadership spans peer review committees, strategic planning groups, and educational programs, impacting both institutional and global radiology practices through innovation, quality improvement, and patient-centered imaging advancements.

Awards & Honors 

Dr. Priya Bhosale has been recognized through competitive leadership program nominations, including the MD Anderson Leadership Institute and the Radiology Leadership Institute. She has been entrusted with chairing influential national committees such as those in the Society for Advanced Body Imaging and the Texas Radiological Society. Her selection for prestigious executive education at Rice University underscores her leadership stature. She has served as an invited moderator, panelist, and presiding officer at leading radiology and oncology conferences, highlighting her expertise and influence. Through her work, she has advanced imaging research, quality standards, and multidisciplinary collaboration, earning respect across academic, clinical, and research communities.

Research Focus

Dr. Priya Bhosale research centers on advanced abdominal and gynecologic cancer imaging, with an emphasis on MRI applications, quantitative imaging, and multi-modality diagnostic strategies. She develops and evaluates imaging biomarkers to improve cancer detection, staging, treatment planning, and response assessment. Her work integrates radiology with pathology and oncology to refine precision medicine approaches. She also investigates quality improvement in imaging protocols and reproducibility in multi-center trials. As an active member of national cancer steering committees and working groups, she contributes to shaping imaging guidelines, fostering innovation, and translating research into practice to enhance outcomes for patients with complex oncologic diseases.

Publication Top Notes

Frequent detection of pancreatic lesions in asymptomatic high-risk individuals

Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head

Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis

Ovarian cancer, the revised FIGO staging system, and the role of imaging

Predictors and patterns of recurrence after definitive chemoradiation for anal cancer

The inguinal canal: anatomy and imaging features of common and uncommon masses

Transport properties of pancreatic cancer describe gemcitabine delivery and response

Imaging of pancreatic adenocarcinoma: update on staging/resectability

Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a 25-year single-institution experience

Cervical cancer: 2018 revised international federation of gynecology and obstetrics staging system and the role of imaging

Imaging and staging of endometrial cancer

Chemotherapy induced liver abnormalities: an imaging perspective

Imaging features of carcinoid tumors of the gastrointestinal tract

Aiyin Chen | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Aiyin Chen | Clinical Trials | Best Researcher Award

Associate Professor at Oregon Health & Science University | United States

Dr. Aiyin Chen is an accomplished ophthalmologist and glaucoma specialist, recognized for her expertise in clinical care, research, and academic leadership. She serves as an Associate Professor in the Department of Ophthalmology at Oregon Health & Science University’s Casey Eye Institute. Dr. Chen’s career bridges advanced patient care with groundbreaking research in glaucoma detection, machine learning risk prediction, and optical coherence tomography applications. She has led and collaborated on multiple NIH-funded projects, contributed extensively to peer-reviewed literature, and worked to improve vision health in underserved populations. Dedicated to advancing ophthalmic science, Dr. Chen’s work continues to shape the future of glaucoma care.

Publication Profile 

Google Scholar

Education 

Dr. Aiyin Chen earned her Bachelor of Arts degree in Biological Sciences with a Neurobiology and Behavior concentration from Cornell University, graduating magna cum laude with distinction. She obtained her Doctor of Medicine with thesis distinction from the University of California, San Francisco (UCSF) School of Medicine. Following medical school, she completed a transitional internship at Atlantic Health Morristown Memorial Hospital and Mount Sinai School of Medicine. Dr. Chen then pursued ophthalmology residency training and a glaucoma fellowship at UCSF. She is certified by the American Board of Ophthalmology and holds active medical licenses in Oregon, Washington, and California, with prior licensure in Nevada.

Experience 

Dr. Aiyin Chen professional journey includes service as a glaucoma specialist at Wellish Vision Institute, and surgical roles at Sunrise Hospital and Box Canyon Surgery Center in Las Vegas. She transitioned to academia at the Casey Eye Institute, Oregon Health & Science University, where she served as Assistant Professor before advancing to Associate Professor. Her clinical expertise encompasses complex glaucoma management and surgery, while her administrative and teaching roles support training the next generation of ophthalmologists. Dr. Chen has been deeply involved in multi-institutional research collaborations, NIH-funded studies, and projects integrating telemedicine and big data analytics to improve glaucoma detection, diagnosis, and patient outcomes.

Awards and Honors 

Dr. Aiyin Chen has earned multiple distinctions throughout her academic and professional career, including thesis distinction during her MD program and recognition for her NIH-funded research contributions in ophthalmology. She has been selected as a K12 Clinical Scientist Institutional Career Development Awardee, underscoring her leadership in translational research. Her grant portfolio includes principal investigator and co-investigator roles on high-impact glaucoma studies funded by the National Eye Institute and National Library of Medicine. Dr. Chen’s scholarship, mentorship, and commitment to improving vision health in underserved communities have established her as a leader in ophthalmic research, earning her recognition among peers in the global vision science community.

Research Focus 

Dr. Aiyin Chen research focuses on advancing glaucoma detection, risk prediction, and disease management through technology-driven approaches. Her work includes developing machine learning models to predict glaucoma onset and progression, exploring the use of optical coherence tomography angiography for early diagnosis, and designing telemedicine-based screening strategies for underserved areas. She has contributed to studies evaluating clinic efficiency through data modeling and examined ocular blood flow in glaucoma patients before and after surgical interventions. With a strong record of NIH-funded research, Dr. Chen’s efforts aim to integrate imaging, big data analytics, and community outreach to improve glaucoma care worldwide.

Publication Top Notes

Does in vitro susceptibility predict clinical outcome in bacterial keratitis?

Measuring glaucomatous focal perfusion loss in the peripapillary retina using OCT angiography

Semaglutide and nonarteritic anterior ischemic optic neuropathy

Scleral intraocular pressure measurement in cadaver eyes pre-and postkeratoprosthesis implantation

Patterns of neural activation associated with exposure to odors from a familiar winner in male golden hamsters

Asian herbal-tobacco cigarettes:“not medicine but less harmful”?

Effect of algorithms and covariates in glaucoma diagnosis with optical coherence tomography angiography

Focal loss analysis of nerve fiber layer reflectance for glaucoma diagnosis

Prediction of multiclass surgical outcomes in glaucoma using multimodal deep learning based on free-text operative notes and structured EHR data

Extraction of active medications and adherence using natural language processing for glaucoma patients

Integrating deep learning with electronic health records for early glaucoma detection: a multi-dimensional machine learning approach

Emerging frontline leaders’ voices in response to COVID-19 crisis

Surgical management of an optic nerve glioma with perineural arachnoidal gliomatosis growth pattern

Optical coherence tomographic angiography detects retinal vascular changes associated with pituitary adenoma

Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Laura Lambrecht | Oncology Pharmaceuticals | Best Researcher Award

Licenced Physician with a doctoral degree (MD) at Department of Medicine V, University Hospital, LMU Munich | Germany

Dr. med. Laura Lambrecht, born in Munich, is a dedicated physician specializing in pneumology and cardiology with a strong research background in experimental adult cardiology. She completed her medical studies at Ludwig-Maximilians-Universität München and the Technical University of Munich, earning her approbation as a physician. Her doctoral research at the Deutsches Herzzentrum München focused on the functional impact of acetylsalicylic acid on platelet function in carriers of genetic variants in the GUCY1A1 gene, associated with coronary heart disease risk. She actively contributes to clinical work, academic research, and professional leadership roles, while also engaging in cultural and educational initiatives.

Publication Profile 

Orcid

Education 

Dr. Laura Lambrecht earned her Allgemeine Hochschulreife from Max-Bon-Gymnasium Germering with top marks. She began her pre-clinical medical studies at Ludwig-Maximilians-Universität München, achieving “gut” in her first medical examination. She continued her clinical medical studies at the Technical University of Munich, also earning “gut,” and successfully passed her second and third medical examinations. She obtained her approbation as a physician in December. Her doctoral work at the Deutsches Herzzentrum München investigated the effects of acetylsalicylic acid on platelet function in genetically predisposed individuals. She holds certifications in Good Clinical Practice (GCP) and is a member of the Young-DZHK research network.

Experience 

Dr. Lambrecht is currently a physician in training for pneumology at the LMU Klinikum, with a prior rotation in cardiology at the same institution. She has also served as a cardiology trainee at the Medizinisches Versorgungszentrum Dachau, a teaching practice of LMU Munich. Her research experience includes experimental adult cardiology at the Deutsches Herzzentrum München in the group of Prof. Dr. H. Schunkert. She has held leadership roles such as assistant representative at the LMU Klinikum. Alongside her clinical career, she has been actively involved in student representation, faculty governance, and medical community engagement through various institutional committees and organizations.

Awards and Honors 

Dr. Lambrecht’s academic achievements include graduating from Max-Bon-Gymnasium Germering with “sehr gut” and consistently strong performance in her medical studies at LMU and TU Munich. She earned her approbation as a physician and secured a place in the prestigious Young-DZHK network, reflecting her recognized potential in cardiovascular research. She received funding for her doctoral project examining the genetic and pharmacological interplay in coronary heart disease. Her leadership as assistant representative and elected student council member also reflects peer recognition. Her commitment to academic excellence, research innovation, and community service positions her as a promising contributor to both clinical and research fields.

Research Focus 

Dr. Lambrecht’s primary research interest lies in cardiovascular pharmacogenetics, particularly the influence of genetic variants on drug response. Her doctoral project focused on the functional effects of acetylsalicylic acid on platelet function in carriers of genetic variants in the coronary heart disease risk gene GUCY1A1. She is interested in translating molecular findings into personalized therapeutic strategies for cardiovascular patients. Her work integrates clinical cardiology with laboratory-based functional assays to better understand genotype-specific treatment responses. Additionally, she engages in interdisciplinary collaboration between cardiology and pneumology, aiming to address comorbid conditions and improve patient care through evidence-based, precision medicine approaches.

Publication Top Notes

Topotecan in a Real-World Small-Cell Lung Cancer Cohort: Prognostic Biomarkers Improve Selection of Patients for Second-Line Treatment.

Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation.

Moutih Rafei | Vaccine Development | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Moutih Rafei | Vaccine Development | Best Researcher Award

Full Professor at Université de Montréal | Canada

Dr. Moutih Rafei is a Full Professor at Université de Montréal specializing in pharmacology, immunology, and molecular biology. He is internationally recognized for his pioneering work in T-cell development, cell therapy, cytokine biology, and vaccine engineering. As founder and CEO of Axiom Services Inc., and former CSO of multiple biotech companies, he bridges academic innovation with industry translation. His career includes over 60 peer-reviewed publications, six patents, and leadership in high-impact immuno-oncology projects. Dr. Rafei is a sought-after keynote speaker, scientific advisor, and grant reviewer, contributing significantly to advancing novel therapeutic platforms for cancer, infectious diseases, and immune system modulation.

Publication Profile 

Google Scholar

Education

Dr. Rafei earned his B.Sc. Honours in Immunology from McGill University, completing a thesis on Giardia lamblia DNA vaccine design. He pursued a PhD in Experimental Medicine at McGill under Dr. Jacques Galipeau, focusing on fusokine-based immunosuppression strategies. He then completed a postdoctoral fellowship at Université de Montréal with Dr. Claude Perreault, studying innate and classical CD8 T-cell development. Complementing his scientific expertise, Dr. Rafei completed the Mini-Entrepreneurship Program at HEC-Poly-UdeM, gaining business strategy training. His multidisciplinary education combines deep immunological research skills with innovation management, positioning him at the intersection of cutting-edge biomedical science, translational medicine, and biotech entrepreneurship.

Experience 

Dr. Rafei’s professional experience spans academia and industry. In academia, he is a Full Professor at Université de Montréal, leading translational hemato-oncology research and mentoring over 60 trainees. In industry, he founded Axiom Services Inc. and co-founded IntelliStem Technologies Inc., guiding R&D in T-cell and stem cell therapies. He served as Chief Scientific Officer for Defense Therapeutics Inc. and IntelliStem, and as Head of Discovery at Medicenna Therapeutics, advancing IL-2 superkine programs to clinical trials. He has presented at major international conferences, secured over $6.5 million in research funding, and consulted for biotech and pharma companies, bridging scientific discovery and product development.

Awards and Honors 

Dr. Rafei has received numerous prestigious awards recognizing his research excellence and leadership. These include the Science Features Excellence Award, recognition among the Most Influential Healthcare Leaders to Watch, and Canada’s Most Visionary Men Leaders in Healthcare. He earned the AAI-Life Technologies Trainee Achievement Award, American Society of Hematology Travel Awards, and the Cedarlane Greenberg Award. His work has been ranked among the Quebec and earned multiple competitive fellowships, including CIHR, Terry Fox Foundation, and FRSQ. He has also been nominated for national innovation awards, consistently  in peer-reviewed competitions and gaining international recognition for scientific impact.

Research Focus 

Dr. Rafei’s research integrates immunology, cell therapy, and biotechnology to develop next-generation therapeutic strategies. His expertise includes T-cell development, cytokine and chemokine biology, fusokine engineering, hematopoietic stem cell transplantation, and vaccine design. He applies high-throughput screening for small-molecule discovery and engineers DNA-, peptide-, protein-, and cell-based vaccines. His current work emphasizes mesenchymal stromal cell platforms (ARM-X) for cancer immunotherapy, immune-oncology drug development, and novel approaches for infectious disease prevention. By combining basic immunology with translational application, Dr. Rafei aims to generate safe, effective, and customizable therapies to treat cancer and modulate immune responses in diverse clinical contexts.

Publication Top Notes

Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner

Mesenchymal stromal cell–derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction

Cell therapy: types, regulation, and clinical benefits

Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis

Nociceptor neurons affect cancer immunosurveillance

A granulocyte-macrophage colony–stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties

Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR 2

Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome

Mesenchymal stem cells beyond regenerative medicine

An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis

Farha Naz | Drug Repurposing | Women Researcher Award

Published on by Top Pharmaceutical

Dr. Farha Naz | Drug Repurposing | Women Researcher Award

Research Scientist at University of Virginia | United States

Dr. Farha Naz is a dynamic and accomplished structural biologist and immunologist, currently serving as a Research Scientist at the University of Virginia, USA. With a Ph.D. in Structural Biology from Jamia Millia Islamia, she has cultivated a distinguished research career focused on infectious diseases, host immunity, and vaccine development. Her postdoctoral work spans prestigious institutions including ICMR and UVA, and she has contributed to impactful translational research on Clostridioides difficile infection, tuberculosis, and host-pathogen interactions. Dr. Naz is also a frequent corresponding author and editorial contributor, demonstrating her leadership and scientific vision in global biomedical research.

Publication Profile 

Google Scholar

Education 

Dr. Farha Naz earned her Ph.D. in Structural Biology from Jamia Millia Islamia, New Delhi, graduating top of her batch in pre-PhD coursework. She completed her M.Sc. in Biotechnology in from Jamia Hamdard. Her B.Sc. from the University of Allahabad was marked by academic distinction, graduating. She completed her 12th and 10th at RDBIC, Allahabad. Her educational journey reflects academic excellence.

Experience 

Dr. Naz began her academic career as a Guest Faculty at the Centre of Bioinformatics, University of Allahabad. She later served as a Temporary Assistant Professor at SHUATS, Allahabad. she held a prestigious ICMR-Centenary Postdoctoral Fellowship at the National Institute of Pathology-ICMR in New Delhi. She then joined the University of Virginia as a Postdoctoral Research Associate in the Division of Infectious Diseases and International Health. Since February  she has been a Research Scientist in the same department, contributing to cutting-edge immunological and translational research in infectious diseases.

Awards and Honors 

Dr. Farha Naz has received multiple academic honors throughout her career. She was awarded the Junior Scientist Award by the Council of Science & Technology, U.P. She graduated as the Faculty Topper of her B.Sc. batch. She has qualified prestigious national fellowships and exams including the CSIR-UGC Fellowship in December, GATE in February, and the CSIR-UGC NET in June. These achievements highlight her consistent academic performance and her early recognition as a promising scientific talent. Her excellence continues through her high-impact research outputs and leadership roles in translational science.

Research Focus 

Dr. Naz’s research centers on host-pathogen interactions, mucosal immunology, and vaccine development, particularly against Clostridioides difficile and Mycobacterium tuberculosis. She investigates the mechanisms by which pathogens evade host immunity and how immune modulation can be leveraged for therapeutic interventions. Her work explores innate immune responses, cytokine signaling, GPCR modulation, and the role of sphingolipids in infection. She has contributed significantly to understanding vaccine adjuvants, humoral responses in recurrent infections, and therapeutic strategies involving immune and nervous system crosstalk. Her translational research aims to advance precision immunotherapy and infectious disease control globally.

Publication Top Notes

Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression

Microtubule affinity-regulating kinase 4: structure, function, and regulation

Elucidation of dietary polyphenolics as potential inhibitor of microtubule affinity regulating kinase 4: in silico and in vitro studies

Designing new kinase inhibitor derivatives as therapeutics against common complex diseases: structural basis of microtubule affinity-regulating kinase 4 (MARK4) inhibition

PKR-inhibitor binds efficiently with human microtubule affinity-regulating kinase 4

Battling COVID-19 pandemic: sphingosine-1-phosphate analogs as an adjunctive therapy?

Cloning, Expression, Purification and Refolding of Microtubule Affinity-Regulating Kinase 4 Expressed in Escherichia coli

Ubiquitin-associated domain of MARK4 provides stability at physiological pH

Atypical PKC phosphorylates microtubule affinity-regulating kinase 4 in vitro

Sphingosine-1-phosphate signaling in Leishmania donovani infection in macrophages

Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays

Human microtubule affinity-regulating kinase 4 is stable at extremes of pH

Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Muhammad Musa Khan | Drug Safety and Risk Management | Best Researcher Award

Associate Researcher at Hainan Institute of Zhejiang University | China

Dr. Muhammad Musa Khan is a Pakistani entomologist and research scientist with an extensive background in agricultural entomology, insect toxicology, and pest management. Currently serving as an Associate Researcher at the Hainan Institute of Zhejiang University, China, he focuses on pesticide toxicity, ecological risk assessment, and resistance management in agroecosystems. His research spans ecological, molecular, and toxicological approaches to pest control. Dr. Khan has published prolifically in high-impact journals and is recognized for advancing sustainable pest management strategies. His collaborative, multidisciplinary work integrates field ecology with molecular diagnostics, benefiting both science and agriculture on a global scale.

Publication Profile 

Google Scholar

Education 

Dr. Khan earned his Ph.D. in Agricultural Entomology and Pest Control from Huazhong Agricultural University, China, where he worked on predator safety in rice ecosystems. He completed his M.Sc. (Hons) in Entomology from the University of Agriculture Faisalabad, Pakistan, researching resistance mechanisms in cotton against sap-sucking pests. His undergraduate degree (B.Sc. Hons) in Agriculture with a specialization in Entomology was obtained from PMAS Arid Agriculture University, Rawalpindi. Additionally, he interned at the Nuclear Institute for Agriculture and Biology, gaining hands-on expertise in biological control agent rearing and field application methods.

Experience 

Dr. Khan currently serves as Associate Researcher at the Hainan Institute of Zhejiang University, China, investigating pesticide toxicity and resistance in brown planthopper and rice ecosystems. His previous role as a Postdoctoral Researcher at South China Agricultural University involved studying the effects of UV light on whiteflies and moths. During his Ph.D., he explored ecotoxicological risks of insecticides on beneficial insects and tested essential oil-based pest repellent strategies. His scientific skillset encompasses molecular biology techniques, gene expression analysis, bioinformatics, and biostatistics. His interdisciplinary approach allows integration of molecular diagnostics with field-level pest management.

Awards and Honors 

Dr. Khan has received significant recognition for his impactful research, including editorial contributions to international journals such as Frontiers in Plant Science. His publications have consistently appeared in top-tier Q1 journals like Journal of Hazardous Materials and Chemosphere. As a corresponding author and equal first author, his contributions are well-acknowledged in international collaborations. His work has received citations and global visibility for its originality in ecological toxicology and entomological innovation. Moreover, his involvement in multiple Chinese institutions and his role in international research networks reflect his growing influence and leadership in the agricultural research community.

Research Focus 

Dr. Khan’s research bridges entomology, toxicology, and molecular biology with a primary focus on insecticide resistance, non-target toxicity, and ecological safety in agroecosystems. He specializes in assessing chemical and environmental stressors on pests and their natural enemies, especially in rice and vegetable production systems. His studies utilize DNA/RNA techniques, gene expression profiling, and biochemical assays to decipher the molecular impact of pesticides and ultraviolet exposure on pest physiology and behavior. He is particularly interested in predator-prey dynamics, pollinator safety, integrated pest management, and sustainable solutions to enhance agricultural productivity while minimizing ecological harm.

Publication Top Notes

Role of insect gut microbiota in pesticide degradation: a review

Metabolic-based insecticide resistance mechanism and ecofriendly approaches for controlling of beet armyworm Spodoptera exigua: a review

Impact of invasive ant species on native fauna across similar habitats under global environmental changes

Lethal and sublethal effects of emamectin benzoate on the rove beetle, Paederus fuscipes, a non-target predator of rice brown planthopper, Nilaparvata lugens

Identification of attractants from plant essential oils for Cyrtorhinus lividipennis, an important predator of rice planthoppers

Role of digestive protease enzymes and related genes in host plant adaptation of a polyphagous pest, Spodoptera frugiperda

Temperature-Dependent Functional Response of Harmonia axyridis (Coleoptera: Coccinellidae) on the Eggs of Spodoptera litura (Lepidoptera: Noctuidae) in …

Lethal and Sublethal Effects of Chlorpyrifos on Biological Traits and Feeding of the Aphidophagous Predator Harmonia axyridis

Sublethal effects of chlorantraniliprole on Paederus fuscipes (Staphylinidae: Coleoptera), a general predator in paddle field

Using a Two-Sex Life Table Tool to Calculate the Fitness of Orius strigicollis as a Predator of Pectinophora gossypiella

Insecticide resistance and detoxification enzymes activity in Nilaparvata lugens Stål against neonicotinoids

Emamectin benzoate induced enzymatic and transcriptional alternation in detoxification mechanism of predatory beetle Paederus fuscipes (Coleoptera: Staphylinidae) at the …

Bright E IGERE | Antibiotic Resistance | Best Researcher Award

Published on by Top Pharmaceutical

Assist. Prof. Dr. Bright E IGERE | Antibiotic Resistance | Best Researcher Award

Senior Lecturer at Delta State University | Nigeria

Assist. Prof. Dr. Bright E. Igere is a distinguished microbiologist and academic with a strong background in microbial genetics, molecular epidemiology, and biotechnology. He currently serves in a pivotal role within his university’s Research and Publication Board and Result Quality Assurance Committee. A dedicated scholar, Dr. Igere has contributed extensively to the scientific community through his multidisciplinary research and peer-reviewed publications. His work spans national and international journals, focusing on antimicrobial resistance, public health, and environmental microbiology. A recipient of several prestigious awards and fellowships, he is committed to advancing scientific knowledge and mentoring the next generation of microbiologists.

Publication Profile 

Google Scholar

Education 

Dr. Bright E. Igere earned his Ph.D. in Microbiology from the University of Fort Hare, South Africa, specializing in microbial genetics and molecular epidemiology. He completed his M.Sc. in Microbiology at Delta State University Abraka, Nigeria, where his research centered on microbial genetics. he obtained a B.Tech. in Biotechnology from Nnamdi Azikiwe University, Awka, a CGPA. He completed his secondary education at Edjeba Secondary School and primary education at Oharisi Modern Primary School, earning his First School Leaving Certificate.

Experience 

Dr. Igere has held multiple academic and administrative roles, currently serving as Secretary of the Research/Publication Board and as a member of the Result Quality Assurance Committee. With extensive experience in microbial research and diagnostics, he has supervised postgraduate theses and mentored young scientists. His work extends beyond teaching into collaborative research, editorial reviews, and institutional governance. Dr. Igere has contributed significantly to microbiological research involving both clinical and environmental isolates, and his collaborations span local and international institutions. His experience in academia is enriched by policy development, grant acquisition, and community health-related research in microbiology and public health.

Awards and Honors 

Dr. Bright E. Igere has received numerous awards and fellowships in recognition of his scientific contributions. He received the AGNES Grant by the African-German Network of Excellence in Science and the Elsevier Reviewers Award. he was honored with a Supervisor-Linked Bursary from the South African Medical Research Council. That same year, he was named Best Emerging Young Researcher in Biological Sciences. He was also awarded an inter-cadre transfer by the Natural Science board and received funding and recognition from Western Delta University for outstanding contributions to molecular training and scientific growth.

Research Focus 

Dr. Igere’s research revolves around microbial genetics, molecular epidemiology, antimicrobial resistance, and biofilm-associated infections. He explores public and environmental health microbiology, focusing on emerging pathogens, toxin-producing strains, and multidrug-resistant organisms in clinical and aquatic ecosystems. His work emphasizes molecular characterization, virulence dynamics, and pathogen surveillance. He has conducted studies on Vibrio cholerae, Bacillus cereus, Klebsiella, and MRSA strains, advancing biofilm therapeutics and eco-health implications. His interdisciplinary research integrates genomics, environmental microbiology, and biotechnology to develop novel therapeutic strategies and inform disease control frameworks. Dr. Igere’s work contributes significantly to global health, food safety, and environmental monitoring.

Publication Top Notes

Prevalence of Multiple Antibiotics Resistant (MAR) Pseudomonas Species in the Final Effluents of Three Municipal Wastewater Treatment Facilities in South Africa

Virulence and Antibiotic Resistance Characteristics of Vibrio Isolates From Rustic Environmental Freshwaters

Antimicrobial and phytochemical evaluation of the leaf, stem bark and root extracts of Cyathula prostrata (L) Blume against some human pathogens

Antibiotic Susceptibility Testing (AST) Reports: A Basis for Environmental/Epidemiological Surveillance and Infection Control Amongst Environmental Vibrio cholerae

Human norovirus contamination in wate8r sources: A systematic review and meta-analysis

Wastewater treatment plants and release: The vase of Odin for emerging bacterial contaminants, resistance and determinant of environmental wellness

Non-serogroup O1/O139 agglutinable Vibrio cholerae: a phylogenetically and genealogically neglected yet emerging potential pathogen of clinical relevance

Meta-synthesis and science mapping analysis of HIV/HPV co-infection: a global perspective with emphasis on Africa

Occurrence, Antibiotic Susceptibility and Genes Encoding Antibacterial Resistance of Salmonella spp. and Escherichia coli From Milk and Meat Sold in Markets of …

Global mapping of cholera vibrio and outbreaks in the pre-millennium development goals (MDG)/sustainable development goals (SDG) and MDGs/SDGs era of 1990–2019

Subrata Kar | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Subrata Kar | Clinical Trials | Best Researcher Award

Subrata Kar at Virginia Commonwealth University | United States

Dr. Subrata Kar is a distinguished interventional cardiologist and academic leader currently serving as Associate Professor of Medicine at Virginia Commonwealth University and Interventional Cardiologist at the Veterans Affairs Medical Center in Richmond, Virginia. With specialization in structural heart disease, peripheral vascular intervention, and advanced heart failure and transplant cardiology, Dr. Kar has held leadership roles at multiple prestigious institutions including UCLA, Texas Tech University, and NYC Health + Hospitals. He has been instrumental in launching advanced cardiology programs, mentoring trainees, and leading clinical and academic departments. His work reflects a deep commitment to patient care, education, and cardiovascular innovation.

Publication Profile 

Orcid

Education 

Dr. Kar earned his Doctor of Osteopathic Medicine from the New York College of Osteopathic Medicine, where he also completed a Neuroanatomy Fellowship. He holds dual bachelor’s degrees in Bio-Mathematics and Biology from Rutgers University. His post-graduate training includes an internal medicine residency at the Cleveland Clinic, followed by a cardiovascular medicine fellowship at the University of Missouri-Columbia. He further specialized with interventional cardiology fellowships at Stony Brook University and UCLA, where he also trained in structural and congenital heart disease. Additionally, he completed an advanced heart failure and transplant cardiology fellowship at NYU Langone Medical Center.

Experience 

Dr. Kar has served in diverse clinical, academic, and leadership roles across major medical institutions in the U.S. Currently an Interventional Cardiologist and Advanced Heart Failure specialist at VCU/VA Medical Center, he previously held senior positions at Middletown Medical, NYC Health + Hospitals, Texas Tech University, and UCLA. His roles have included Division Chief, Director of Interventional Cardiology, and Chair of Fellowship Selection Committees. He has also worked as a hospitalist at the Cleveland Clinic and a clinical instructor at UCLA. His experience reflects comprehensive expertise in interventional cardiology, structural heart interventions, and academic program development.

Awards and Honors 

Dr. Kar has received recognition for both clinical excellence and academic leadership. At UCLA and Texas Tech, he was instrumental in program development and fellowship training, earning him leadership roles such as Chair of the Academic Cardiology Section of the American College of Cardiology (Texas Chapter). He has been invited to present at national cardiology conferences and served on key committees evaluating trainee competency. His pioneering clinical program launches, particularly in interventional cardiology at Coney Island Hospital, highlight his innovation and impact. His mentorship and contributions to cardiology education have also been widely commended by academic and hospital leadership.

Research Focus 

Dr. Kar’s research centers on structural heart disease, adult congenital heart defects, interventional cardiology techniques, and advanced heart failure therapies. He has explored minimally invasive cardiovascular interventions, radiation reduction in catheterization procedures (KAR RAD study), and cardiac CT applications. He has presented nationally on outcomes in percutaneous valve procedures and congenital heart disease management. His work also includes developing safety protocols and training programs in cardiac catheterization labs. Through his research, he integrates clinical innovation with academic insight, advancing cardiovascular treatment and education, especially in underserved populations. His mentoring of trainees in research further amplifies his academic reach.

Publication Top Notes

Application and Outcomes of Minimal-Dose Versus Standard-Dose Radiation in Peripheral Endovascular Intervention (KAR Endovascular Study)

Kelly Yoo | Precision Medicine | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Kelly Yoo | Precision Medicine | Best Scholar Award

Kelly Yoo at Stanford University | United States

Dr. Kelly H. Yoo is a physician-scientist specializing in neurosurgery and neuro-oncology, currently conducting postdoctoral research at Stanford University. Her work bridges translational neuroscience, radiosurgery, and artificial intelligence in clinical applications. She has authored numerous peer-reviewed articles and case studies on stereotactic radiosurgery, spinal disorders, and brain metastases. Dr. Yoo has received multiple international awards and fellowships for her academic excellence and research leadership. As a committed member of professional organizations and advisory boards, she contributes to global health, clinical innovation, and medical education. Her research efforts aim to improve patient outcomes through technology-enhanced, precision-targeted therapies.

Publication Profile 

Scopus

Education 

Dr. Kelly Yoo earned her International Baccalaureate Diploma and graduated. She later obtained her MD with top distinction and completed her Doctorate (Dr. med., magna cum laude) from Heidelberg University School of Medicine. Her academic path included rigorous clinical, research, and methodological training. She completed multiple advanced certifications, including GCP, IRB, and Clinical Trial Investigator courses. She studied Fundamental Neuroscience for Neuroimaging at Johns Hopkins University and holds licenses and fellowships from institutions in Germany and the U.S., further enhancing her global medical and scientific competency.

Experience 

Dr. Yoo currently serves as a postdoctoral fellow at Stanford University, focusing on clinical and translational research in neurosurgery. She completed a clinician-scientist residency track in Baden-Württemberg and has worked across Europe and North America in academic medical centers. She is active in multiple professional societies, including AANS, CNS, and EANO. Dr. Yoo has held leadership roles in Stanford’s postdoc community and initiated several mentorship and international programs. Her academic career includes significant contributions to radiosurgical research and spinal navigation, leveraging both clinical experience and data-driven methodologies to explore innovative therapeutic solutions.

Awards and Honors 

Dr. Kelly Yoo has received numerous prestigious accolades, including the SPARK at Stanford Grant Award, Wu Tsai Neurosciences Interdisciplinary Fellowship, and multiple scholarships from the German Academic International Network (GAIN). She was also awarded the E-Fellows Gifted Education Scholarship and earned top academic distinctions from Heidelberg University and the International Baccalaureate program. She has consistently ranked in the top percentile across educational stages and received first-place honors in international mathematics competitions. Her recognitions reflect a long-standing commitment to academic excellence, scientific innovation, and leadership in neuroscience, medicine, and global health initiatives.

Research Focus 

Dr. Yoo’s research primarily centers on stereotactic radiosurgery, neuro-oncology, spinal disorders, and the integration of AI and neuroimaging into surgical planning and treatment. She investigates the clinical applications of advanced radiological techniques in treating recurrent and metastatic brain and spinal tumors. Her recent work explores synergistic effects between radiosurgery and immunotherapy and the cost-effectiveness of neurosurgical interventions. She also contributes to studies on spinal navigation, robotic-assisted surgery, and PET/MRI-guided interventions. Her interdisciplinary focus aims to enhance precision medicine and outcome prediction models in neurosurgery by blending clinical insight with computational innovation.

Publication Top Notes

Suspected and surgically managed cauda equina syndrome nationwide: epidemiological trends and socioeconomic factors influencing access to care

Trends in Sacroiliac Joint Fusion Costs and Utilization in the Privately Insured Population

Song Chian | Neuropharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Song Chian | Neuropharmacology | Best Researcher Award

Professor at Zhejiang police college | China

Prof. Song Chian is the Director of the Forensic Physical and Chemical Teaching and Research Section at the Criminal Science and Technology College of Zhejiang Police College. With a specialized focus in drug toxicology, Prof. Song has significantly contributed to forensic science education and research. Over the past five years, he has led and participated in multiple national and provincial research initiatives, producing over 20 academic publications. His work explores the mechanisms of drug addiction and its implications in forensic toxicology. Prof. Song remains a key academic leader, mentoring future forensic professionals and contributing to policy and practical advancements in the field.

Publication Profile  

Scopus

Education 

Prof. Song Chian received his academic training in forensic science and toxicology, laying a strong foundation for his specialized work in forensic drug analysis. He completed his undergraduate and graduate studies in criminal science and technology, followed by advanced training in toxicology with a focus on the physiological and biochemical mechanisms of drug addiction. Throughout his academic career, he has actively participated in continuing education programs, academic workshops, and research methodology training both nationally and provincially. His education has equipped him with the knowledge and analytical skills essential for high-level research and teaching in forensic toxicology.

Experience 

Prof. Song Chian currently serves as Director of the Forensic Physical and Chemical Teaching and Research Section at Zhejiang Police College. Over the years, he has accumulated extensive experience in forensic toxicology, both in academia and applied research. He has served as Principal Investigator for projects funded by the Zhejiang Provincial Basic Public Welfare Research Program and has collaborated on major national initiatives. His expertise spans forensic drug detection, mechanisms of addiction, and analytical techniques in toxicology. In his academic role, he has mentored students, developed specialized curricula, and published widely in the field, shaping the next generation of forensic scientists.

Awards and Honors 

Prof. Song Chian has been recognized for his contributions to forensic science research and education. Although specific awards are not listed, his leadership roles and funding successes—such as being Principal Investigator for major research projects funded by the Zhejiang Provincial Basic Public Welfare Research Program—demonstrate academic and professional recognition. His selection to contribute to national-level special projects and National Natural Science Foundation initiatives further reflects his credibility and standing in the research community. His continuous publication record and position as director within Zhejiang Police College indicate high-level institutional trust and respect within the field of forensic toxicology.

Research Focus 

Prof. Song Chian’s primary research focus lies in the toxicology of drugs, with a particular emphasis on the mechanisms of drug addiction. His work aims to uncover the physiological and chemical pathways that underpin addictive behaviors and drug-induced toxicity. By integrating forensic science with pharmacology, Prof. Song’s research supports both legal investigations and public health policies. His approach combines analytical chemistry techniques with behavioral science models to understand drug interactions in the human body. Through his projects and academic publications, he contributes to improved drug detection methods, toxicological risk assessment, and the development of prevention strategies for substance abuse.

Publication Top Notes

  • Fentanyl Induces Novel Conditioned Place Preference in Adult Zebrafish, Disrupts Neurotransmitter Homeostasis, and Triggers Behavioral Changes